New drug approved for lack of certain white blood cells

(HealthDay)—The U.S. Food and Drug Administration has approved the drug tbo-filgrastim to treat certain cancer patients undergoing chemotherapy who have a condition called severe neutropenia, the FDA said in a news release.

Neutropenia, sometimes triggered by certain , is characterized by a decrease in infection-fighting called neutrophils. Tbo-filgrastim stimulates the bone marrow to increase output of neutrophils. The new drug, injected about 24 hours after chemotherapy is administered, is meant for adults who do not have cancers of the blood or bone marrow, the FDA said.

Tbo-filgrastim was evaluated among 348 adults with who received the chemotherapy drugs doxorubicin and docetaxel. People who received the tbo-filgrastim recovered from severe neutropenia in an average of 1.1 days, compared with 3.8 days among adults given a placebo, the agency said.

Bone pain was the most common side effect of the new drug observed in clinical testing, the FDA said.

Tbo-filgrastim is produced by Sicor Biotech, a unit of the Israeli pharmaceutical firm Teva Corp.

More information: To learn more about neutropenia, visit the Mayo Clinic.

add to favorites email to friend print save as pdf

Related Stories

Zaltrap approved for advanced colorectal cancer

Aug 04, 2012

(HealthDay) -- Zaltrap (ziv-afilbercept) has been approved by the U.S. Food and Drug Administration in combination with a FOLFIRI chemotherapy regimen for adults with advanced metastatic (spreading) colorectal cancer, the ...

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

22 hours ago

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments